Primary hypothyroidism is a known risk factor for pituitary hyperplasia, which develops symptoms due to compression of the optic chiasma and increased intracranial pressure. As pituitary hyperplasia is known to improve after levothyroxine replacement therapy, there are no reports of a long clinical course of pituitary hyperplasia due to primary hypothyroidism. We describe a case of follow-up over 16 years for pathologically diagnosed pituitary hyperplasia due to primary hypothyroidism with positive thyroid stimulation blocking antibody. Repeated enlargement and shrinkage were confirmed, but observations also suggested that the pituitary gland did not always return to normal size.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511211 | PMC |
| http://dx.doi.org/10.7759/cureus.43823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cohort profile: Multicenter Networks for Ideal Outcomes of Rare Pediatric Endocrine and Metabolic Diseases in Korea (OUTSPREAD study).
Ann Pediatr Endocrinol Metab
December 2024
Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
Rare endocrine diseases are complex conditions that require lifelong specialized care due to their chronic nature and associated long-term complications. In Korea, a lack of nationwide data on clinical practice and outcomes has limited progress in patient care. Therefore, the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Disease (OUTSPREAD) study was initiated.
View Article and Find Full Text PDFPituitary Gigantism in an Adolescent Girl With Postsurgical Residual Disease Treated With Lanreotide.
JCEM Case Rep
January 2025
Department of Pediatrics, Children's Nebraska and University of Nebraska Medical Center, Omaha, NE 68104, USA.
Pituitary gigantism (PG) is a rare endocrine disorder that may present with multiple pituitary hormone abnormalities in pediatric patients. A hallmark presentation is accelerated growth due to growth hormone (GH) excess. Current treatment modalities include surgery, radiation, and medical therapy.
View Article and Find Full Text PDFEvaluation of sleep health in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
J Clin Endocrinol Metab
November 2024
Division of Pediatric Endocrinology, University of Minnesota Medical School, Minneapolis, MN.
Article Synopsis
- The study investigates sleep health in children and adolescents with congenital adrenal hyperplasia (CAH) using wrist actigraphy and sleep questionnaires.
- It found that these children had poorer sleep duration, efficiency, and more awakenings compared to healthy peers, particularly related to hydrocortisone medication timing.
- The results indicate that sleep issues are significant for children with CAH, highlighting the need for attention in clinical practice and further research.
Pituitary Acrogigantism: From the Past to the Future.
Front Horm Res
November 2024
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.
Pituitary acrogigantism is a very rare disease that is caused by chronic growth hormone (GH) axis excess that begins during childhood and adolescence. As such, it represents one of the most severe manifestations of acromegaly. In most cases, acrogigantism is caused by a pituitary adenoma, but hyperplasia can also accompany the adenoma or rarely occur alone.
View Article and Find Full Text PDFContinuous Glucose Monitoring-Derived Glycemic Phenotyping of Childhood Hypoglycemia due to Hyperinsulinism: A Year-long Prospective Nationwide Observational Study.
J Diabetes Sci Technol
November 2024
Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.
Article Synopsis
- The study investigates the glycemic patterns in children with congenital hyperinsulinism (HI) using Continuous Glucose Monitoring (CGM) over a 12-month period to provide better insights for future treatments.
- It involved 45 patients, revealing a consistent risk of hypoglycemia, especially early in the morning, but showed that CGM did not effectively reduce these episodes and the device's accuracy was found to be poor.
- Despite high dissatisfaction among patients and families regarding CGM usage, qualitative feedback indicated that it helped them understand glycemic patterns and make behavior adjustments to reduce hypoglycemia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!